

# Quarterly Commentary

4Q25

## Market Review

The year 2025 witnessed what we believe are robust returns in US equities, marked by double-digit gains across all major indices and Small Caps achieving a new all-time high price level. However, despite these impressive performances, the market experienced extreme price fluctuations and leadership that was concentrated in historically narrow segments.

Reflecting on the start of 2025, Small Caps entered the year with an optimistic outlook. Prices were slightly lower than their post-election highs in November 2024, but investors remained confident in the new Trump administration's pro-growth and deregulatory economic plan. This optimism persisted until February, when the White House announced a comprehensive new tariff strategy, which caused stock prices to plummet by over 20% in a matter of weeks. By early April, however, with stocks seemingly discounting in a worst-case scenario, the market caught wind of potential modifications to the tariff policies that could mitigate their impact. This shift in investor sentiment led to a dramatic turnaround, with the Russell 2000 Growth Index surging nearly 50% over the next six months.

Around two weeks into the fourth quarter, concerns about credit quality in the private credit and regional banking sectors emerged. These concerns were underscored by the bankruptcy filing of auto parts supplier First Brands and allegations of fraud at subprime auto lender Tricolor. This situation led JPMorgan CEO Jamie Dimon to remark, "when you see one cockroach, there are probably more." Despite the sharp gains experienced since April, these developments triggered a 10% correction in the Russell 2000 Growth Index. We were heartened that the Conestoga strategies (which had struggled during the massive rally that started in April), provided the downside capture we would have expected during the selloff from mid-October to mid-November. This downturn was followed by a recovery in late November, fueled by renewed optimism for further interest rate cuts from the Federal Reserve and robust third-quarter corporate earnings results.

*(Continued on following page.)*

## Performance\* (Total Net Returns as of 12/31/25)

	4Q25	1 Year	3 Years	5 Years	10 Years	Since Inception 12/31/1998
Conestoga Small Cap Composite (Net)	-1.89%	-10.13%	6.30%	0.27%	9.74%	10.43%
Russell 2000 Growth Index	1.22%	13.01%	15.59%	3.18%	9.57%	7.28%
						Since 1/31/2017
Conestoga SMid Cap Composite (Net)	-2.71%	-4.71%	10.34%	2.01%		11.44%
Russell 2500 Growth Index	0.33%	10.31%	14.32%	2.98%		10.46%
						Since 12/31/2019
Conestoga Micro Cap Composite (Net)	-1.91%	16.24%	9.31%	-0.04%		9.80%
Russell Microcap Growth Index	2.14%	21.84%	17.46%	2.81%		8.25%
						Since 3/31/2010
Conestoga Mid Cap Composite (Net)	-5.75%	-4.73%	6.89%	0.20%	9.86%	10.21%
Russell Midcap Growth Index	-3.70%	8.66%	18.64%	6.65%	12.49%	12.70%

\*Periods longer than One Year are Annualized. Please see additional important disclosures in the fully compliant GIPS presentations at the end of this commentary. Russell 2000 Growth Index measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted growth values. Russell 2500 Growth Index measures the performance of those Russell 2500 companies with higher price-to-book ratios and higher forecasted growth values. Russell Microcap Growth Index measures the performance of those Russell Microcap companies with higher price-to-book ratios and higher forecasted growth values. Russell Midcap Growth Index measures the performance of those Russell Midcap companies with higher price-to-book ratios and higher forecasted growth values.

## Market Review (Continued)

As we highlighted at the end of the third quarter, the 50% rise in the Russell 2000 Growth Index from April to October was characterized by return leadership from an extremely narrow subset of stocks, and this narrow leadership continued throughout the fourth quarter. By the end of 2025, the 10 best returning stocks in the Index represented 46% of the overall Index returns, with the 20 best performers representing 71% of the returns. To put these numbers into context, across the past five positive return years in the Russell 2000 Growth Index, the 10 best performing stocks averaged 23% of the Index's total returns and the 20 best averaged 35% of its return.

A notable development in the fourth quarter was the emergence of Small Cap Biotech/Pharmaceutical stock outperformance. After comprising just 11% of the Russell 2000 Growth Index's total returns year-to-date through the end of the third quarter, Biotech/Pharmaceuticals represented 132% of the Index's total returns in the fourth quarter alone. In other words, the gains in Small Cap Biotech/Pharmaceutical stocks in the fourth quarter more than offset the combined losses experienced by Technology, Industrial, and Consumer Discretionary stocks and single-handedly drove the overall gains of the Russell 2000 Growth Index.

While our Composites' returns saw some benefits in the fourth quarter from the pullback of the most speculative winners of the April to October rally, which we had minimal exposure to, these gains were more than counterbalanced by the sharp rise in Biotech and Pharmaceutical stocks where we also had limited exposure. Notable to us this year was the elevated number of days when our strategies' returns rose or fell by more than 1% compared to their respective benchmarks. For example, in our Small Cap Growth strategy, there were 40 days in 2025 in which our returns were 1% above or below those of the Russell 2000 Growth Index. For context, since inception, our strategy has averaged less than 11 such days in any given calendar year. Considering our high quality, low beta, conservative growth investment discipline, such wide performance swings are highly unusual and, in our view, emblematic of how abnormal the stock market returns were in 2025.

Importantly, while the 50% rally in the Russell 2000 Growth Index from April to October was characterized by a narrow group of high-beta, low-profitability, and speculative stocks—considered "low quality"—the leadership in the fourth quarter also remained "low quality" but to a lesser extent. Historically, new Small Cap bull markets start with a year of such "low quality" leadership, with the most significant gains typically occurring in the first six months. Following this period, "high quality" stocks, such as those we hold, gradually start to close the gap, eventually reclaiming leadership. Notably, in the recent period from mid-October to year-end, profitable stocks in the Russell 2000 Growth Index outperformed their unprofitable counterparts by over 5%, despite trailing by more than 58% during the early-April to mid-October rally.

Looking ahead we think the outlook for Small Cap stocks is bright. After experiencing two years of negative earnings growth, Small Caps achieved nearly 9% earnings growth in 2025 and are projected to grow by an additional 32% in 2026. This is in stark contrast to the anticipated 13% earnings growth in Large Caps. Moreover, Small Caps are currently trading at a nearly 25% discount to Large Caps. Given the anticipated economic growth tailwinds from last year's pro-growth and deregulatory government policies, we believe there is a compelling case for Small Caps to outperform Large Caps for the first time since 2020. This could potentially herald a new, extended cycle of Small Cap outperformance.

## Firm Update

As of December 31, 2025, Conestoga's total assets were **\$6.9 Bil**. Assets within our four primary institutional investment strategies were:

**\$4.8 Bil**

Small Cap Growth

**\$2.0 Bil**

SMid Cap Growth

**\$55 Mil**

Micro Cap Growth

**\$15 Mil**

Mid Cap Growth

As we mentioned in last quarter's commentary, we are pleased to announce that several promotions took effect on December 31, 2025:


- **Derek Johnston** was promoted to **Managing Partner and Co-Portfolio Manager Small Cap**. Derek joined Conestoga in 2015, was named Co-Portfolio Manager for the SMid Cap Growth strategy in 2016 and became a partner in 2018.
- **David Neiderer** was promoted to **Managing Partner and Director of Research**. David joined Conestoga in 2013 and became a partner in 2018. He will continue to serve as a Co-Portfolio Manager for the firm's Micro Cap Growth strategy.
- **Jeffrey Riggs** was promoted to **Managing Partner and Managing Director – Head of Global Distribution**. Since joining Conestoga in 2016, Jeff has served as Institutional Sales and Client Service Officer. He became a partner in 2019.
- **Bronwyn Dewey** was promoted to **Partner and Director – Sales & Client Service**. Bronwyn has been with Conestoga since 2022 in an Advisor Relations role and her expanded responsibilities will now encompass all distribution channels.
- **Zach Wilson** was promoted to **Partner**. Zach serves as Operations Specialist and Assistant Compliance Officer and joined Conestoga in June 2022.

### Closing of the Conestoga Mid Cap Growth Strategy

After a thorough evaluation of the Conestoga Mid Cap Growth strategy's asset level, performance, and growth opportunities, the firm's leadership has determined that it is in the best interest of our clients and the firm to close and fully wind down the strategy. Our target date for closing the strategy is January 31, 2026.

To our Mid Cap clients, we want to extend our sincere appreciation for your trust and for being a client of the strategy. We value the partnership we have built and remain committed to delivering high-quality investment solutions and services across the rest of our platform.

## Small Cap Composite Net Performance (as of 12/31/25)\*



\*Sources: Conestoga, Russell Investments. Periods Longer than One Year are Annualized. Composite Inception is December 31, 1998. Please see additional important disclosures in the fully compliant GIPS presentations at the end of this commentary. Russell 2000 Growth Index measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted growth values.

## Small Cap Composite – 4Q25 Performance & Attribution

The Conestoga Small Cap Composite posted a total return of -1.89% net-of-fees in the fourth quarter of 2025, underperforming the Russell 2000 Growth Index return of 1.22%. Market returns were volatile in the quarter, with the first two weeks seeing a continuation of the sharp rally from the early April lows until concerns over rising credit risks triggered a sudden 10% correction over the next six weeks, before ultimately finishing the quarter strong on back of interest rate cuts and robust third quarter earnings reports. From a macro perspective, we noted in the quarter that while “low quality” stocks again outperformed, the degree of outperformance was more muted than it had been earlier in the year. After trailing by more than 23% across 2Q and 3Q, profitable stocks in the Russell 2000 Growth Index lagged unprofitable ones by just 8% in 4Q. More importantly, once the “low quality” rally peaked on October 15th, profitable stocks in the Russell 2000 Growth Index bested unprofitable ones by more than 5% through year-end 2025, and our strategy outperformed by more than 2% over the same period.

While our returns benefited in the fourth quarter from the pullback in the most speculative winners of the April to October rally, these gains were offset by negative sector allocation and stock selection in the Health Care sector. Specifically, Small Cap biotechnology and pharmaceuticals stocks, where we are materially underweight the Index, represented 132% of the Russell 2000 Growth's total returns in the fourth quarter, versus just 11% year-to-date through the end of the third quarter. Four of our six Health Care stocks were positive contributors to performance in the fourth quarter, led by Repligen Corp. (RGEN) and Vericel Corp. (VCEL), while Stevanato Group SpA (STVN) and LeMaitre Vascular, Inc. (LMAT) were the detractors. The challenge was keeping up with the overall Health Care sector's 18% overall returns, led by biotechnology and pharmaceuticals' gains of 28% and 19%, respectively.

Returns were also challenging in the Industrials sector, where six of our sixteen positions added to returns and our more cyclically exposed holdings struggled. AAON, Inc. (AAON) and Construction Partners, Inc. (ROAD) lagged after reporting weaker than expected 3Q25 results, while Trex Co., Inc. (TREX) continued to suffer from competitive pressures and the slower and longer-lasting housing and remodeling environment.

On the positive side, stock selection was particularly strong in Financials and Basic Materials, while sector allocation drove gains in Consumer Discretionary. Within Financials, Clearwater Analytics Holdings, Inc. (CWAN) outperformed dramatically on back of a mid-quarter announcement that the company would be acquired. In Basic Materials, RBC Bearings, Inc. (RBC) was a standout thanks to strong tailwinds in their aerospace and defense businesses, as well as robust operating leverage, margin expansion, and free cash flow conversion. Finally, our gains in Consumer Discretionary were driven by a combination of our relatively low weight in the sector, on top of positive relative performance in our two holdings.

## Small Cap Composite – Full Year 2025 Performance & Attribution

Moving to the full year, the Composite outperformed the Russell 2000 Growth Index through early May, when the U.S. and China agreed to temporarily halt the newly introduced tariffs and begin negotiations on a broader deal, further accelerating the rally which had already taken the Index up over 20% since April 8th. And then, once that rally peaked on October 15th, the Composite again outperformed the Russell 2000 Growth Index through year-end. In fact, the entirety of our Small Cap Composite's relative performance challenges came during the April 8th–October 15th period when the Russell 2000 Growth Index rallied over 49% and was led higher by a historically narrow subset of stocks with unprofitable, high beta, and long duration characteristics. In total, our Composite trailed the Russell 2000 Growth Index in 2025 with a return of -10.13% net of fees versus the benchmark's return of 13.01%.

While challenging from a relative performance perspective, sharp "low quality" rallies like we experienced in 2025 historically have taken place at the very beginning of new Small Cap bull markets. These "low quality" rallies tend to last roughly a full year but see their largest gains in the first six months before trailing off and finally ceding leadership back to "high quality" over the next six months. That historical precedent is important here because while unprofitable stocks in the Russell 2000 Growth Index outperformed their profitable peers by more than 58% in the roughly six months between April 8th and October 15th market rally, they then lagged by -5% from mid-October through year-end, providing hope that while it could be choppy for a few more months, the worst of the "low quality" headwind may be behind us.

In terms of full year performance effects, stock selection was most challenging in Technology, where fears of the "AI eating Software" theme gripped the market and caused significant multiple contraction across the group, with SPS Commerce, Inc. (SPSC), Vertex, Inc. (VERX), and Descartes Systems Group, Inc. (DSGX) experiencing the largest negative effects in our portfolio.

Within Industrials, 9 of our 22 stocks were positive contributors to performance, while weakness in three of our holdings had a particularly adverse impact on overall results. AAON, Inc. (AAON) suffered from a slowdown in demand for HVAC equipment following several years of strong growth. Trex Co., Inc. (TREX), as mentioned earlier, struggled in the face of competitive pressures and an extended slowdown in the residential repair and remodel market, while Transcat, Inc. (TRNS) saw persistent organic service revenue weakness and margin compression following a series of acquisitions which weighed on profitability and investor sentiment.

Finally, our sector underweight in Health Care – and specifically our minimal exposure to the Small Cap biotechnology and pharmaceuticals industries – hindered relative returns as these two industries were among the best performing industries in the Russell 2000 Growth Index in 2025. One bright spot was solid gains in our high conviction position in Repligen Corp. (RGEN), but it was outweighed by weakness in Vericel Corp. (VCEL), Neogen Corp. (NGEN), and Azenta, Inc. (AZTA).

## Small Cap Composite – 4Q25 Top 5 Leaders

### 1. Clearwater Analytics Holdings, Inc. (CWAN)

CWAN provides cloud-based investment accounting and analytics software to institutional investors and insurers. Shares significantly outperformed in 4Q25 following the announcement that the company would be acquired, which drove a re-rating toward the agreed transaction value. The acquisition highlighted the strategic value of CWAN's highly recurring revenue model, strong client retention, and critical role within institutional investment operations.

### 2. RBC Bearings, Inc. (RBC)

RBC designs and manufactures precision bearings and engineered components for aerospace, defense, and industrial markets. The stock outperformed in 4Q25 as aerospace demand remained resilient, defense orders accelerated, and operating leverage drove margin expansion. Investors reacted positively to strong free-cash-flow conversion and continued successful integration of prior acquisitions. RBC's exposure to long-cycle aerospace programs and mission-critical components supported earnings durability.

### 3. Repligen Corp. (RGEN)

RGEN supplies bioprocessing equipment and consumables used in biologic drug manufacturing. Shares rebounded strongly as evidence mounted that industry destocking had bottomed and order trends were stabilizing. Improved visibility into 2026 growth, combined with disciplined cost controls, drove operating leverage expectations higher. The market re-rated the stock as investors looked past near-term volatility and focused on RGEN's high-quality consumables mix, strong market positions, and long-term biologics growth tailwinds.

### 4. Digi International, Inc. (DGII)

DGII provides connectivity solutions, including routers, gateways, and embedded systems. The stock performed well in the quarter as recurring services revenue grew faster than expected and margins expanded with mix shift toward software and subscriptions. Improved demand visibility in industrial and infrastructure end markets, along with disciplined expense management, supported earnings upside. Investors increasingly valued the company's transition toward a higher-quality, recurring-revenue business model, differentiating it from more hardware-centric small-cap technology peers.

### 5. Novanta, Inc. (NOVT)

NOVT provides technology solutions to medical and advanced industrial OEMs, specializing in photonics, vision, and precision motion. The company outperformed in the fourth quarter following a strong earnings report highlighted by double-digit growth in its Advanced Surgery business. Management noted that bookings grew 17% year-over-year, signaling robust future demand as customer inventory levels normalize. We believe NOVT's ability to exceed profit expectations while navigating a complex macro environment demonstrates the durability of its diversified, high-quality business model.

## Small Cap Composite – 4Q25 Bottom 5 Laggards

### 1. Stevanato Group SpA (STVN)

STVN is a global provider of high-performance drug containment and delivery solutions for the pharmaceutical industry. The stock underperformed during the quarter, pressured by two key factors. First, the company's engineering segment reported a 20% decline in revenue. Although the segment represents only about 15% of total revenue, its turnaround has taken longer than anticipated, weighing on overall results. Second, investor concerns have grown around the potential impact of FDA approval and the introduction of oral GLP-1 therapies. Given STVN's focus on injectable drug delivery, uncertainty regarding the eventual market share of oral alternatives within the broader GLP-1 category has created near-term uncertainty.

### 2. FirstService Corp. (FSV)

FSV is a leading provider of essential property services to residential and commercial customers in North America. Shares detracted from performance after the company reported third-quarter revenues that fell short of consensus expectations, despite meeting earnings per share estimates. Investors expressed concern over softer organic growth and near-term headwinds in certain service lines. We continue to believe the company's recurring revenue model and leadership position in fragmented markets remain intact for the long term.

### 3. AAON, Inc. (AAON)

AAON designs and manufactures high-efficiency HVAC systems for commercial and industrial applications. Despite solid 3Q25 results, shares retreated as backward-looking industry channel checks highlighted ERP-related delivery delays and extended lead times. With a relatively new CEO still establishing credibility with the Street, execution concerns—even if transitory—weighed on sentiment given the rapid pace of innovation in the data center cooling market. We believe operational improvements are underway and AAON's strong hyperscaler relationships position the company well for renewed growth.

### 4. Construction Partners, Inc. (ROAD)

ROAD is a vertically integrated civil infrastructure company constructing roadways and highways across the Sunbelt. The stock underperformed during the quarter following the release of fiscal fourth-quarter results, where earnings per share missed analyst estimates. While the company delivered better-than-expected revenue growth and highlighted a record backlog, the market focused on the bottom-line shortfall. We remain confident in the company's ability to benefit from sustained infrastructure demand and its disciplined acquisition strategy.

### 5. Trex Co., Inc. (TREX)

TREX manufactures composite decking and railing products for residential outdoor living markets. Performance was pressured in 4Q25 due to heightened competitive intensity, including increased pricing pressure and share competition from both established and lower-priced alternatives, which weighed on volumes and margins. While the company maintains market leadership and a strong brand, the stock reflected investor concern around rising competition and the sustainability of near-term profitability in a more crowded marketplace. We sold the stock in 4Q25.



### Small Cap Composite – 4Q25 Buys\*

#### 1. Badger Meter, Inc. (BMI)

BMI is a leading provider of water meters and connected smart-metering solutions primarily for municipal water utilities. The company exhibits hallmarks of high quality, operating in an oligopolistic water-metering market providing must-have solutions, replacement-driven recurring revenue, healthy capital structure, and good management. Decades of consistent execution, recurring revenues, and attractive free-cash-flow generation supports BMI's ability to grow durably and compound value through economic cycles.

#### 2. Karman Holdings, Inc. (KRMN)

KRMN is a defense technology company specializing in the design and manufacturing of highly engineered, mission-critical systems for a diverse set of existing and next-generation space, missiles, hypersonic, and defense programs. KRMN generates mid-teens or better organic revenue growth that is complimented by tuck-in M&A. They sell to over 70 customers across more than 100 defense programs. Over 90% of revenue is IP protected and nearly 90% of revenue is bought by their customers on a sole source basis.

### Small Cap Composite – 4Q25 Sells\*

#### 1. Trex Co., Inc. (TREX)

TREX manufactures composite decking and railing products for residential outdoor living markets. Performance was pressured in 4Q25 due to heightened competitive intensity, including increased pricing pressure and share competition from both established and lower-priced alternatives, which weighed on volumes and margins. While the company maintains market leadership and a strong brand, the stock reflected investor concern around rising competition and the sustainability of near-term profitability in a more crowded marketplace. We sold the stock in 4Q25.


#### 2. Mesa Laboratories, Inc. (MLAB)

MLAB provides quality-control instruments, consumables, and services to regulated industries, including life sciences and healthcare. MLAB represented a small position within the small-cap strategy and we lacked sufficient conviction in the company's long-term growth prospects to increase our exposure. Consequently, we exited the position. The company's operating results have been pressured by end-market weakness, particularly in cell and gene therapy and in China. In addition, MLAB's acquisition strategy—especially within clinical genomics—has not delivered the growth we initially anticipated. With limited organic growth opportunities and a balance sheet that constrains further acquisitions, we believe MLAB's overall growth prospects remain limited.

Conestoga added to positions on three occasions and trimmed stocks on three occasions during the fourth quarter.

*\*Portfolio holdings shown above experienced material activity during the quarter.*

## Small Cap Composite – Sector Weightings (as of 12/31/25)



Source: FactSet, Conestoga. Sectors are defined according to the ICB industry definitions.


## Small Cap Composite – Top Ten Equity Holdings (as of 12/31/25)

Symbol	Company Name	Sector	% of Assets
CWST	Casella Waste Systems, Inc.	Utilities	4.40%
RBC	RBC Bearings, Inc.	Basic Materials	4.39%
DSGX	Descartes Systems Group, Inc.	Technology	3.75%
ROAD	Construction Partners, Inc.	Industrials	3.62%
ESE	ESCO Technologies, Inc.	Industrials	3.51%
BCPC	Balchem Corp.	Basic Materials	3.17%
NOVT	Novanta, Inc.	Technology	3.13%
CSW	CSW Industrials, Inc.	Industrials	3.11%
MMSI	Merit Medical Systems, Inc.	Health Care	3.02%
FSV	FirstService Corp.	Real Estate	2.91%
Total within the Composite:			35.01%

The positions represent Conestoga Capital Advisors largest equity holdings based on the aggregate dollar value of positions held in the client accounts that are included in the Small Cap Composite. All information is provided for informational purposes only and should not be deemed as a recommendation to buy the securities mentioned. Sectors are defined according to the ICB industry definitions.



## SMid Cap Composite Net Performance (as of 12/31/25)\*



\*Sources: Conestoga, Russell Investments. Composite creation date is December 31, 2013. Please see additional important disclosures in the fully compliant GIPS presentations at the end of this commentary. Russell 2500 Growth Index measures the performance of those Russell 2500 companies with higher price-to-book ratios and higher forecasted growth values.

## SMid Cap Composite – 4Q25 Performance & Attribution

The Conestoga SMid Cap Composite trailed the Russell 2500 Growth Index in the fourth quarter with a total return of -2.71% net-of-fees versus the benchmark return of 0.33%. Relative performance was volatile throughout the quarter. A sharp market drawdown which saw the Index decline by more than -10% from October 27th through November 20th, provided the portfolio with the strong downside capture we've come to expect during such periods. The market rallied sharply however from November 20th through year-end and the portfolio gave back much of its relative gains. For the quarter, negative stock selection effects in the Industrials and Real Estate sectors were the primary drivers of underperformance, while an underweight to the highly volatile biotechnology industry also detracted from relative returns. These losses were partially offset by positive stock selection in the Financials and Basic Materials sectors. From a factor perspective, a "tug-of-war" between high-quality and low-quality factors persisted throughout the quarter, with unprofitable companies once again pulling away and outperforming their profitable counterparts, providing a significant headwind to relative performance.

Stock selection proved most challenging in the Industrials sector, with the biggest losses coming from Trex Co., Inc. (TREX) and Construction Partners, Inc. (ROAD). Performance for TREX was pressured due to heightened competitive intensity, including increased pricing pressure and share competition. ROAD was one of the portfolio's biggest winners through the first nine months of the year but gave back some of its gains in the fourth quarter after earnings results missed analyst estimates. These losses were partially mitigated by strong performance from Jack Henry & Associates, Inc. (JKHY) and CSW Industrials, Inc. (CSW). Both companies benefited from a macro environment that rewarded essential, stable growth businesses with low sensitivity to economic and rate volatility, as investors favored visibility and durability over cyclical exposure late in the year.

Four of our five portfolio holdings in the Health Care sector were additive to relative returns with our high-conviction position in Repligen Corp. (RGEN) leading the way higher. Shares rallied in the fourth quarter as the broader bioprocessing market showed clear signs of recovery with the company delivering encouraging order growth. Stevanato Group SpA (STVN) was the only detractor in the sector. While demand for its high-value syringes and vials remained robust, the slower-than-expected recovery in its engineering segment dampened overall results. The biggest headwind for relative performance in the sector however was our lack of exposure to the biotechnology industry. After a prolonged period of valuation compression, the group rallied 21% during the quarter as stabilized interest-rate expectations improved sentiment toward long-duration growth sectors.

On the positive side, stock selection in the Financials, Basic Materials, and Utilities sectors provided a boost to relative results. Within Financials, Clearwater Analytics Holdings, Inc. (CWAN) surged following the announcement that the company would be acquired, which drove a re-rating toward the agreed transaction value. Both of our holdings in Basic Materials added value with RBC Bearings, Inc. (RBC) being the biggest winner. Shares rallied on strong quarterly results, driven by robust demand in the aerospace and industrial markets. Our sole position in Utilities, Casella Waste Systems, Inc. (CWST), added to relative returns during the quarter, particularly when stocks started selling off in late October.

## SMid Cap Composite – Full Year 2025 Performance & Attribution

The Conestoga SMid Cap Composite trailed the Russell 2500 Growth Index for the full year 2025 with a total return of -4.71% net-of-fees versus the benchmark return of 10.31%. Almost all the underperformance occurred from the market bottom on April 8th through October 27th when the Index rallied 46%. Relative performance during this period was significantly impacted by a market environment that favored low-quality, high-beta, and unprofitable companies. Furthermore, the Index experienced remarkably narrow leadership, with a majority of the benchmark's gains concentrated in a small group of top contributors—most of which were concentrated in AI-related themes, hardware, and defense stocks.

For the annual period, negative stock selection effects in the Technology, Industrials, and Health Care sectors were the primary drivers of underperformance, while selection and allocation effects in Consumer Discretionary, Consumer Staples, and Financials sectors provided the most meaningful offsets. Stock selection proved most challenging in the Technology sector, where several long-term holdings faced valuation compression. SPS Commerce, Inc. (SPSC), Descartes Systems Group, Inc. (DSGX), and Tyler Technologies, Inc. (TYL) were the largest detractors within the sector. SPSC and DSGX both saw shares retreat as investors rotated out of software-as-a-service (SaaS) providers in favor of the hardware and AI-infrastructure names that dominated the Index returns. Similarly, TYL shares faced pressure as the market prioritized immediate AI-driven growth over steady, long-term cloud transitions.

Within the Industrials sector, Trex Co., Inc. (TREX) and Watsco, Inc. (WSO) also lagged. TREX struggled due to competitive pressures, while WSO shares were impacted by cooling demand for HVAC equipment following several years of record-breaking growth. While the benchmark's Industrials' performance was bolstered by defense-related stocks, our lack of exposure to defense contractors weighed on relative results. Within Health Care, the biggest headwind for relative returns was our lack of exposure to the biotechnology industry, which rallied 33% for the year.

On the positive side, stock selection in the Consumer Discretionary sector provided a boost to relative returns. Rollins, Inc. (ROL) was the largest contributor to portfolio returns for the year as the company continued to demonstrate its defensive growth characteristics, posting consistent organic revenue gains and margin expansion. In addition, our large underweight to the Financials sector and lack of exposure to the Consumer Staples sector provided a relative boost as both areas significantly underperformed the benchmark.

## SMid Cap Composite – 4Q25 Top 5 Leaders

### 1. Repligen Corp. (RGEN)

RGEN supplies bioprocessing equipment and consumables used in biologic drug manufacturing. Shares rebounded strongly as evidence mounted that industry destocking had bottomed and order trends were stabilizing. Improved visibility into 2026 growth, combined with disciplined cost controls, drove operating leverage expectations higher. The market re-rated the stock as investors looked past near-term volatility and focused on RGEN's high-quality consumables mix, strong market positions, and long-term biologics growth tailwinds.

### 2. RBC Bearings, Inc. (RBC)

RBC designs and manufactures precision bearings and engineered components for aerospace, defense, and industrial markets. The stock outperformed in 4Q25 as aerospace demand remained resilient, defense orders accelerated, and operating leverage drove margin expansion. Investors reacted positively to strong free-cash-flow conversion and continued successful integration of prior acquisitions. RBC's exposure to long-cycle aerospace programs and mission-critical components supported earnings durability.

### 3. Jack Henry & Associates, Inc. (JKHY)

JKHY constitutes a leading provider of technology solutions and payment processing services primarily for community banks and credit unions. The stock performed well after the company reported solid fiscal first-quarter results, characterized by steady top-line growth and successful contract wins for its modernization solutions. Despite industry consolidation headwinds, JKHY's consistent sales momentum and ability to secure long-term client relationships highlight the resilience of its business model and its critical role in the financial services infrastructure.

### 4. CSW Industrials, Inc. (CSW)

CSW operates as a diversified industrial growth company with well-established brands in the HVAC, plumbing, and engineered building solutions markets. Despite reporting the first organic decline in twelve quarters in its key Contractor Solutions segment, the weak report was well understood given the challenging residential HVAC equipment sales market in 2025. We believe the stock's outperformance in the quarter was aided by an early December upgrade by J.P. Morgan as well as the company closing its second large acquisition this year (Motors & Armatures Parts (MARS Parts), which increased the company's exposure to HVAC repair so it's less reliant on replacement of equipment.

### 5. Clearwater Analytics Holdings, Inc. (CWAN)

CWAN provides cloud-based investment accounting and analytics software to institutional investors and insurers. Shares significantly outperformed in 4Q25 following the announcement that the company would be acquired, which drove a re-rating toward the agreed transaction value. The acquisition highlighted the strategic value of CWAN's highly recurring revenue model, strong client retention, and critical role within institutional investment operations.

## SMid Cap Composite – 4Q25 Bottom 5 Laggards

### 1. FirstService Corp. (FSV)

FSV is a leading provider of essential property services to residential and commercial customers in North America. Shares detracted from performance after the company reported third-quarter revenues that fell short of consensus expectations, despite meeting earnings per share estimates. Investors expressed concern over softer organic growth and near-term headwinds in certain service lines. We continue to believe the company's recurring revenue model and leadership position in fragmented markets remain intact for the long term.

### 2. Pool Corp. (POOL)

POOL is the largest distributor of swimming pool supplies, equipment, and related outdoor products in the United States. The shares lagged as demand remained pressured by a slower housing and discretionary spending environment. Reduced new pool construction and renovation weighed on volumes. The company's maintenance business is holding up well but deflation in its tricolor chemical business is pressuring revenue. Despite these headwinds, POOL's scale, distribution advantages, and strong cash generation continue to support its long-term business fundamentals.

### 3. Trex Co., Inc. (TREX)

TREX manufactures composite decking and railing products for residential outdoor living markets. Performance was pressured in 4Q25 due to heightened competitive intensity, including increased pricing pressure and share competition from both established and lower-priced alternatives, which weighed on volumes and margins. While the company maintains market leadership and a strong brand, the stock reflected investor concern around rising competition and the sustainability of near-term profitability in a more crowded marketplace. We sold the stock in 4Q25.

### 4. Stevanato Group SpA (STVN)

STVN is a global provider of high-performance drug containment and delivery solutions for the pharmaceutical industry. The stock underperformed during the quarter, pressured by two key factors. First, the company's engineering segment reported a 20% decline in revenue. Although the segment represents only about 15% of total revenue, its turnaround has taken longer than anticipated, weighing on overall results. Second, investor concerns have grown around the potential impact of FDA approval and the introduction of oral GLP-1 therapies. Given STVN's focus on injectable drug delivery, uncertainty regarding the eventual market share of oral alternatives within the broader GLP-1 category has created near-term uncertainty.

### 5. Construction Partners, Inc. (ROAD)

ROAD is a vertically integrated civil infrastructure company constructing roadways and highways across the Sunbelt. The stock underperformed during the quarter following the release of fiscal fourth-quarter results, where earnings per share missed analyst estimates. While the company delivered better-than-expected revenue growth and highlighted a record backlog, the market focused on the bottom-line shortfall. We remain confident in the company's ability to benefit from sustained infrastructure demand and its disciplined acquisition strategy.

## SMid Cap Composite – 4Q25 Buys\*

### 1. AAON, Inc. (AAON)

AAON designs and manufactures high-efficiency HVAC systems tailored for commercial and industrial applications. As a long-standing holding in our Small Cap strategy, the recent pullback in the stock has created an appealing entry point for our SMid cap strategy. AAON exhibits strong growth prospects, driven by its significant exposure to the data center market through its BASX division, as well as its robust competitive position in the semi-custom rooftop sector.

### 2. Karman Holdings, Inc. (KRMN)

KRMN is a defense technology company specializing in the design and manufacturing of highly engineered, mission-critical systems for a diverse set of existing and next-generation space, missiles, hypersonic, and defense programs. KRMN generates mid-teens or better organic revenue growth that is complimented by tuck-in M&A. They sell to over 70 customers across more than 100 defense programs. Over 90% of revenue is IP protected and nearly 90% of revenue is bought by their customers on a sole source basis.

## SMid Cap Composite – 4Q25 Sells\*

### 1. Generac Holdings, Inc. (GNRC)

GNRC manufactures power generation and energy storage equipment for residential, commercial, and industrial customers. The position was sold in 4Q as near-term fundamentals remain challenged by demand normalization, elevated channel inventories, and continued margin pressure, limiting visibility into a sustained earnings recovery. While long-term opportunities in energy resilience remain attractive, increased cyclical and execution uncertainty reduce alignment with our quality and stability criteria, leading us to reallocate capital toward opportunities with clearer growth durability.


### 2. Trex Co., Inc. (TREX)

TREX manufactures composite decking and railing products for residential outdoor living markets. Performance was pressured in 4Q25 due to heightened competitive intensity, including increased pricing pressure and share competition from both established and lower-priced alternatives, which weighed on volumes and margins. While the company maintains market leadership and a strong brand, the stock reflected investor concern around rising competition and the sustainability of near-term profitability in a more crowded marketplace. We sold the stock in 4Q25.

Conestoga added to positions on three occasions and trimmed stocks on eight occasions during the fourth quarter.

*\*Portfolio holdings shown above experienced material activity during the quarter.*

## SMid Cap Composite – Sector Weightings (as of 12/31/25)




Source: FactSet, Conestoga. Sectors are defined according to the ICB industry definitions.

## SMid Cap Composite – Top Ten Equity Holdings (as of 12/31/25)

Symbol	Company Name	Sector	% of Assets
CWST	Casella Waste Systems, Inc.	Utilities	4.70%
RBC	RBC Bearings, Inc.	Basic Materials	4.14%
ROL	Rollins, Inc.	Consumer Discretionary	4.06%
ROAD	Construction Partners, Inc.	Industrials	3.61%
RGEN	Repligen Corp.	Health Care	3.22%
FSV	FirstService Corp.	Real Estate	3.18%
DSGX	Descartes Systems Group, Inc.	Technology	3.14%
GWRE	Guidewire Software, Inc.	Technology	3.14%
CSW	CSW Industrials, Inc.	Industrials	3.09%
MMSI	Merit Medical Systems, Inc.	Health Care	2.94%
Total within the Composite:			35.22%

The positions represent Conestoga Capital Advisors largest equity holdings based on the aggregate dollar value of positions held in the client accounts that are included in the SMid Cap Composite. All information is provided for informational purposes only and should not be deemed as a recommendation to buy the securities mentioned. Sectors are defined according to the ICB industry definitions.

## Micro Cap Composite – Net Performance (as of 12/31/25)\*



\*Sources: Conestoga, Russell Investments. Composite creation date is December 31, 2019. Please see additional important disclosures in the fully compliant GIPS presentations at the end of this commentary. Russell Microcap Growth Index measures the performance of those Russell Microcap companies with higher price-to-book ratios and higher forecasted growth values.

## Micro Cap Composite – 4Q25 Performance & Attribution

The Conestoga Micro Cap Composite delivered results in 2025 in line with our objective of protecting capital during periods of weak market returns while also keeping pace during periods of strong market returns. 2025 was a roller coaster year of returns for Micro Caps as they began the year in the midst of a bear market, sharply reversed course from the bottom of that bear market with a six-month long and 81% rally, consolidated those gains in October/November, and ultimately rallied again into year-end. As that unfolded, our Composite outperformed the Russell Microcap Growth Index during the selloff into the April 8th market bottom, trailed the Index through the “low quality” snapback rally from April 8th– October 15th, outperformed again during the October 15th–November 20th correction, and kept pace in the rally into year-end. Ultimately, the Composite posted total returns of -1.91% net-of-fees in the fourth quarter and 16.24% net-of-fees in full year 2025, trailing the 2.14% and 21.84% gains in the Russell Microcap Growth Index in the fourth quarter and full year, respectively.

In terms of performance, the Composite experienced positive sector allocation effects and strong stock selection in Consumer Staples, Financials, and Telecom, while sector allocation effects in the Health Care and Industrials sectors were the primary drivers of underperformance. Within Health Care, biotechnology proved to be the largest headwind to performance due to a combination of both stock selection and sector allocation, due to our underweight positioning. From a stock perspective, Alpha Teknova, Inc. (TKNO) was our largest detractor, as the current extended period of inventory normalization weighed on customer purchases, pressuring margins. Phreesia, Inc. (PHR) also struggled in the quarter on back of more conservative forward guidance provided in their third quarter results, though we were encouraged by their improving profitability and expanding network of clients. Partially offsetting this were strong gains from IRadimed Corp. (IRMD), which rose 28% after delivering record third quarter results and announcing a special cash dividend, as well as positive contributions from Vericel Corp. (VCEL).

Within Industrials, Planet Labs PBC (PL) was a standout performer again, rising over 51% in the quarter on back of stronger than expected revenue growth and profitability in the third quarter, as well as a record reported backlog. On the flip side, i3 Verticals, Inc. (IIIV) sagged after providing lower than expected near-term guidance in their quarterly results, but we believe the longer-term outlook remains bright given their positioning for strong recurring revenue growth. Bowman Consulting Group, Ltd. (BWMN) also suffered after reporting weaker-than-expected third quarter revenue results which weighed on investor sentiment in what had been a strong year-to-date performer.

Elsewhere in the portfolio, returns in the Consumer Staples and Energy sectors delivered positive impacts to the Composite. Within Consumer Staples, our two holdings – Mama’s Creations, Inc. (MAMA) and Vita Coco Co., Inc. (COCO) – rose 28% and 25% respectively in the quarter. MAMA’s surge was driven by their strong revenue increase in the third quarter and overall execution on their strategy to capture market share through new product placements at major retailers like Costco and Target. COCO also posted stronger than expected results in the third quarter, evidencing both its leadership in its category and its ability to translate brand strength into consistent cash generation.

## Micro Cap Composite – Full Year 2025 Performance & Attribution

Turning to the full year results, the Conestoga Micro Cap Composite rose 16.24% net-of-fees in 2025, trailing the 21.84% gains in the Russell Micro Cap Growth Index. Highlighting these returns were a few standout performers. Planet Labs PLC (PL) provided a total return of 388% in 2025 as the company secured significant new contract wins with government and defense sectors, accelerated revenue growth, and achieved profitability earlier than expected. Willdan Group, Inc. (WLDN) posted a full year total return of 172%, successfully capitalizing on surging demand for energy efficiency and grid modernization services, particularly from the AI-driven data center market and large government contracts.

From a sector perspective, Industrials, Consumer Staples, and Consumer Discretionary provided the most impacts on the Composite's returns. Within Industrials, while PL and WLDN were the key drivers, positive contributions also came from Construction Partners, Inc. (ROAD), Montrose Environmental Group, Inc. (MEG), Bowman Consulting Group, Ltd. (BWMN), and CryoPort, Inc. (CYX). Offsetting these gains were lagging performance effects from Transcat, Inc. (TRNS) and SoundThinking, Inc. (SSTI).

Our Consumer Staples returns were driven by strong stock selection effects from gains in our two holdings, Mama's Creations, Inc. (MAMA) and Vita Coco Co., Inc. (COCO), which rose 69% and 44% respectively in the full year. In Consumer Discretionary, our gains were more related to sector allocation effects given our overall underweight position, but Universal Technical Institute, Inc. (UTI) stood out with positive returns in a sector which fell by over 10% in the full year.

Other notable stock contributors to full-year performance included Digi International, Inc. (DGII), Palomar Holdings, Inc. (PLMR), Olo, Inc. (OLO), and ElectroVaya, Inc. (ELVA).



## Micro Cap Composite – 4Q25 Top 5 Leaders

### 1. Planet Labs PBC (PL)

PL is a leading provider of global, daily satellite imagery and geospatial solutions. The stock rallied during the quarter after the company reported accelerating revenue growth of 33% and its fourth consecutive quarter of adjusted EBITDA profitability. Investors responded positively to a record backlog, which grew over 200% year-over-year, driven largely by expanding contracts in the defense and intelligence sectors. We remain encouraged by PL's business model transition from a capital-intensive buildout phase to one of scalable, high-margin data generation.

### 2. IRadimed Corp. (IRMD)

IRMD develops, manufactures, and markets MRI-compatible medical devices, including infusion pump systems and patient monitors. The company delivered record third-quarter revenue and earnings, prompting management to raise full-year guidance. This strong operational performance, combined with the announcement of a special cash dividend, underscored the company's financial health and commitment to shareholder returns. We believe IRMD's niche leadership and innovative product pipeline continue to offer a compelling growth trajectory.

### 3. Mama's Creation, Inc. (MAMA)

MAMA markets and manufactures fresh, clean-label prepared foods for grocers and retailers nationwide. Shares surged in December after the company announced a 50% year-over-year increase in quarterly revenue, fueled by both organic gains and the successful integration of the Crown 1 acquisition. Adjusted EBITDA more than doubled as the company leveraged its expanded manufacturing footprint. We view this execution as validation of their strategy to capture market share through new product placements at major retailers like Costco and Target.

### 4. Vita Coco Company, Inc. (COCO)

COCO develops and markets coconut water and better-for-you beverage products. Shares advanced as brand momentum remained strong and revenue growth outpaced expectations. Improved pricing discipline and cost efficiencies supported margin expansion, while international and adjacent product growth enhanced the outlook. Investors rewarded the company's category leadership and its ability to translate brand strength into consistent cash generation.

### 5. Electrovaya, Inc. (ELVA)

ELVA designs and manufactures lithium-ion battery systems for industrial mobility and energy storage applications. Shares traded higher as order activity strengthened and progress toward commercial scale improved revenue visibility. Advancements in customer adoption and manufacturing execution supported optimism around future growth. The market responded positively to their differentiated battery technology and increasing exposure to electrification trends across material handling and industrial end markets.

## Micro Cap Composite – 4Q25 Bottom 5 Laggards

### 1. Alpha Teknova, Inc. (TKNO)

TKNO is a leading provider of critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. The company reported a solid quarter and pointed to positive leading indicators in end markets driven by biotech funding and nice growth with large pharma companies. That said, the positive leading indicators have not yet translated into sales, and investors continue with a "wait-and-see" approach to a recovery in early-stage biotech funding.

### 2. Phreesia, Inc. (PHR)

PHR provides a SaaS-based platform that automates patient intake, payments, and clinical data for healthcare organizations. The stock declined in the fourth quarter following the release of fiscal third-quarter results. While PHR exceeded estimates for both revenue and earnings, the company provided forward revenue guidance that was viewed as conservative by investors, prompting valuation compression. Despite the volatility, we remain encouraged by PHR's improving profitability and its expanding network of healthcare services clients.

### 3. Universal Technical Institute, Inc. (UTI)

UTI is a leading provider of vocational education for automotive, skilled trades, and energy sectors. Shares sold off in November after the company issued a financial outlook for fiscal 2026 that fell below Wall Street expectations. Although UTI reported strong fiscal fourth-quarter results that beat estimates on both the top and bottom lines, the softer forward guidance regarding EBITDA and earnings growth weighed on investor sentiment. We continue to monitor their execution on diversifying program offerings.

### 4. i3 Verticals, Inc. (IIIV)

IIIV delivers integrated software and payment solutions to the public sector and healthcare markets. The stock faced pressure during the quarter after management issued a conservative growth forecast for fiscal 2026. The company cited timing delays in project implementations within its utilities and transportation verticals as a primary factor. While the near-term outlook disappointed the market, we believe IIIV remains well-positioned to drive recurring revenue growth through its software-led strategy over the multi-year horizon.

### 5. Bowman Consulting Group Ltd. (BWMN)

BWMN provides multi-disciplinary engineering, planning, and consulting services to the built environment. Shares retraced gains in the fourth quarter after the company reported third-quarter revenue that significantly missed consensus estimates, despite an earnings beat. The revenue shortfall, combined with subsequent insider selling activity in December, contributed to negative sentiment. We remain focused on BWMN's long-term opportunity to consolidate the fragmented engineering services market and expand its infrastructure capabilities.

Source: FactSet

### Micro Cap Composite – 4Q25 Buys\*

#### 1. Electroveya, Inc. (ELVA)

ELVA designs and manufactures lithium-ion battery systems for industrial mobility and energy-storage applications. The company benefits from differentiated battery technology, improving customer adoption, and growing exposure to long-cycle industrial electrification trends. As execution has strengthened, revenue visibility and margin potential have improved, supporting a clearer path to sustainable cash generation. The company's mission-critical applications and increasing scale align with our focus on businesses capable of improving quality characteristics over time.

#### 2. Oddity Tech Ltd. (ODD)

ODD is a consumer technology platform built to transform the global beauty and wellness industry. ODD builds and scales digital-first brands with artificial intelligence, molecular discovery, computer vision, and a data science-based online platform. The company monetizes all products on a direct-to-consumer basis and has no wholesale exposure. ODD has scaled their business quickly, achieving greater than 20% operating margins while still growing their revenue base by greater than 20% to an estimated \$800 million in 2025. The company is founder-led by Oran Holtzman, who also owns more than 20% of the shares outstanding.


### Micro Cap Composite – 4Q25 Sells\*

None.

Conestoga added positions on eleven occasions and trimmed positions on eight occasions during the fourth quarter.

*\*Portfolio holdings shown above experienced material activity during the quarter.*

## Micro Cap Composite – Sector Weightings (as of 12/31/25)




Source: FactSet Research Systems and Conestoga. Sectors are defined according to the ICB industry definitions.

## Micro Cap Composite – Top Ten Equity Holdings (as of 12/31/25)

Symbol	Company Name	Sector	% of Assets
PLMR	Palomar Holdings, Inc.	Financials	5.03%
VCEL	Vericel Corp.	Health Care	4.57%
MAMA	Mama's Creations, Inc.	Consumer Staples	4.54%
UTI	Universal Technical Institute, Inc.	Consumer Discretionary	4.17%
QTWO	Q2 Holdings, Inc.	Technology	3.86%
WLDN	Willdan Group, Inc.	Industrials	3.84%
ELVA	Electrovaya, Inc.	Industrials	3.77%
IRMD	IRadimed Corp.	Health Care	3.74%
BLFS	BioLife Solutions, Inc.	Health Care	3.44%
BWMN	Bowman Consulting Group, Ltd.	Industrials	3.42%
<b>Total within the Composite:</b>			<b>40.38%</b>

The positions represent Conestoga Capital Advisors largest equity holdings based on the aggregate dollar value of positions held in the client accounts that are included in the Micro Cap Composite. All information is provided for informational purposes only and should not be deemed as a recommendation to buy the securities mentioned. Sectors are defined according to the ICB industry definitions.

## Mid Cap Composite Net Performance (as of 12/31/25)\*



\*Sources: Conestoga, Russell Investments. Composite creation date is March 31, 2010. Please see additional important disclosures in the fully compliant GIPS presentations at the end of this commentary. Russell Midcap Growth Index measures the performance of those Russell Midcap companies with higher price-to-book ratios and higher forecasted growth values.

## Mid Cap Composite – 4Q25 Performance & Attribution

The Conestoga Mid Cap Composite trailed the Russell Midcap Growth Index in the fourth quarter with a total return of -5.75% net-of-fees versus the benchmark return of -3.70%. Negative stock selection effects in the Technology and Industrials sectors were the primary drivers of underperformance, though these were partially offset by positive sector allocation effects. The Utilities and Health Care sectors were modestly additive to relative performance. From a factor perspective, the quarter was characterized by a mixed environment that lacked the clear "low-quality" or "AI-hardware" leadership seen earlier in the year. However, the portfolio's emphasis on high-quality, steady earners continued to face headwinds in a market focused on short-term macroeconomic shifts and valuation resets.

Stock selection proved most challenging in the Technology and Industrials sectors. Within Technology, Bentley Systems, Inc. (BSY) and Tyler Technologies, Inc. (TYL), were the largest detractors. BSY traded lower as revenue growth decelerated modestly and margins were affected by increased investment in product development and go-to-market initiatives. TYL lagged in the quarter as investor preference shifted away from software names. While the company's long-term fundamentals and recurring revenue model remain intact, near-term growth visibility and valuation considerations weighed on relative performance.

Losses in the Industrials sector were led by our positions in Generac Holdings, Inc. (GNRC) and AAON, Inc. (AAON). GNRC shares fell sharply after the company lowered its full-year 2025 outlook, citing a weaker power outage environment that dampened demand for its residential standby generators. AAON declined after the company reported operational challenges related to a recent system rollout.

On the positive side, the Utilities and Health Care sectors provided a boost to relative results. Our lone position in Utilities, Waste Connections, Inc. (WCN), was flat for the quarter but the stability of the company's earnings and cash flows provided the downside capture we've come to expect. Gains in Health Care were broad-based with five of our six positions adding value. Repligen Corp. (RGEN) and IDEXX Laboratories, Inc. (IDXX) were the two largest contributors to portfolio returns for the quarter. RGEN shares rallied as the bioprocessing market showed signs of stabilization and renewed demand for its life sciences tools. IDXX continued to demonstrate its high-quality, defensive growth characteristics, posting robust quarterly results driven by consistent demand in its veterinary diagnostics business.

## Mid Cap Composite – Full Year 2025 Performance & Attribution

The Conestoga Mid Cap Composite trailed the Russell Midcap Growth Index for the full year 2025 with a total return of -4.73% net-of-fees versus the benchmark return of 8.66%. Relative performance was significantly impacted by a market environment that persistently favored low-quality, high-beta, and unprofitable companies, particularly following the market bottom on April 8, 2025. Furthermore, the Index experienced remarkably narrow leadership, with the majority of the benchmark's gains concentrated in a small handful of top contributors, many of which were AI-related hardware, defense, and power infrastructure stocks. For the annual period, negative stock selection effects in the Technology and Industrials sectors were the primary drivers of underperformance.

In the Technology sector, several quality holdings faced significant valuation compression as capital flowed into more speculative AI names within the benchmark. Gartner, Inc. (IT), Tyler Technologies, Inc. (TYL), and Roper Technologies, Inc. (ROP) were the largest detractors within the sector.

Within the Industrials sector, performance also lagged as investors bypassed traditional industrial quality names to concentrate capital in defense-related stocks and energy infrastructure winners. From a stock selection perspective, our positions in Verisk Analytics, Inc. (VRSK) and Watsco, Inc. (WSO) were the biggest laggards.

Select stock contributors in various sectors provided the only offsets to broad underperformance. HEICO Corp. (HEI.A), IDEXX Laboratories, Inc. (IDXX) and Rollins, Inc. (ROL) were the three largest contributors to portfolio returns for the year.

## Mid Cap Composite – 4Q25 Top 5 Leaders

### 1. Jack Henry & Associates, Inc. (JKHY):

JKHY constitutes a leading provider of technology solutions and payment processing services primarily for community banks and credit unions. The stock performed well after the company reported solid fiscal first-quarter results, characterized by steady top-line growth and successful contract wins for its modernization solutions. Despite industry consolidation headwinds, JKHY's consistent sales momentum and ability to secure long-term client relationships highlight the resilience of its business model and its critical role in the financial services infrastructure.

### 2. Repligen Corp. (RGEN)

RGEN supplies bioprocessing equipment and consumables used in biologic drug manufacturing. Shares rebounded strongly as evidence mounted that industry destocking had bottomed and order trends were stabilizing. Improved visibility into 2026 growth, combined with disciplined cost controls, drove operating leverage expectations higher. The market re-rated the stock as investors looked past near-term volatility and focused on RGEN's high-quality consumables mix, strong market positions, and long-term biologics growth tailwinds.

### 3. Rollins, Inc. (ROL)

ROL is a premier global consumer and commercial services company, providing essential pest control services through brands such as Orkin. The company's stock appreciated following a solid 3Q25 earnings report that demonstrated its consistent pricing power and recurring revenue stability. The company reported organic growth of 7.2%-led by commercial organic growth of 8.4%. The company also showed strong incremental margins of 35%. Additionally, a double-digit increase in the quarterly dividend highlighted management's confidence in future cash flows. ROL remains a core holding due to its defensive characteristics and ability to compound earnings through various economic cycles.

### 4. IDEXX Laboratories, Inc. (IDXX)

IDXX is the industry leader in providing instruments (and consumables) used in diagnostics, detection, and information systems for veterinary, food, and water testing applications. IDXX continued its trend of earnings beats and continued to show resilient organic revenue growth in the face of weak veterinary traffic trends. Shares continued to re-rate back to average historical valuation.

### 5. West Pharmaceutical Services, Inc. (WST)

WST manufactures packaging components and delivery systems for injectable drugs and healthcare products. The company's strong performance was driven by continued momentum in its High-Value Products segment, particularly for GLP-1 obesity and diabetes therapies. Management indicated that previous destocking headwinds have moderated, paving the way for a return to sustainable volume growth. We believe WST remains a critical partner to the pharmaceutical industry, well-positioned to benefit from the long-term secular trends toward biologic and injectable medicines.

Source: FactSet

## Mid Cap Composite – 4Q25 Bottom 5 Laggards

### 1. Pool Corp. (POOL)

POOL is the largest distributor of swimming pool supplies, equipment, and related outdoor products in the United States. The shares lagged as demand remained pressured by a slower housing and discretionary spending environment. Reduced new pool construction and renovation weighed on volumes. The company's maintenance business is holding up well but deflation in its tricolor chemical business is pressuring revenue. Despite these headwinds, POOL's scale, distribution advantages, and strong cash generation continue to support its long-term business fundamentals.

### 2. Veeva Systems, Inc. (VEEV)

VEEV is a leading provider of cloud-based software solutions specifically designed for the global life sciences industry. Despite maintaining a dominant market position and raising full-year guidance, the stock retreated in the fourth quarter. The decline was largely driven by a broader sector rotation out of higher-valuation software names and investor caution regarding the timing of large enterprise deal closures. We remain confident in VEEV's strategic value to the pharmaceutical industry and its expanding product runway in data and commercial cloud.

### 3. CoStar Group, Inc. (CSGP)

CSGP, the leading provider of commercial and residential real estate data and marketplace platforms, experienced share price pressure in the fourth quarter. The primary headwind was the company's aggressive investment in its Homes.com platform, as elevated spending materially weighed on overall profitability. In addition, Apartment.com bookings fell short of investor expectations. While CSGP's expansion into the residential real estate market represents a meaningful long-term growth opportunity, the substantial marketing investment required to gain market share pressured near-term margins. Further weighing on sentiment, media reports late in the quarter suggested that Google may enter the for-sale home listings market, raising concerns about increased competition and contributing to valuation pressure.

### 4. Bentley Systems, Inc. (BSY)


BSY provides infrastructure engineering software used in the design and operation of transportation, utilities, and industrial assets. The stock traded lower as revenue growth decelerated modestly and margins were affected by increased investment in product development and go-to-market initiatives. Concerns around project timing and public-sector spending also weighed on sentiment. Despite durable demand for infrastructure software, the market reacted to near-term execution and growth variability.

### 5. Generac Holdings, Inc. (GNRC)

GNRC manufactures power generation and energy storage equipment for residential, commercial, and industrial markets. Performance fell short during the quarter as demand remained pressured by channel inventory normalization and a slower housing backdrop. Margin recovery progressed more gradually than anticipated, keeping investor expectations restrained. While long-term opportunities in energy resilience and distributed generation remain attractive, near-term fundamentals continued to influence relative performance during the quarter.

The Mid Cap Composite did not experience any new buys or complete sells, nor did it have any partial activity during the fourth quarter.

## Mid Cap Composite – Sector Weightings (as of 12/31/25)



Source: FactSet, Conestoga. Sectors are defined according to the ICB industry definitions.

## Mid Cap Composite – Top Ten Equity Holdings (as of 12/31/25)

Symbol	Company Name	Sector	% of Assets
ROL	Rollins, Inc.	Consumer Discretionary	6.42%
HEIA	HEICO Corp.	Industrials	6.39%
IDXX	IDEXX Laboratories, Inc.	Health Care	4.98%
WCN	Waste Connections, Inc.	Utilities	4.91%
VRSK	Verisk Analytics, Inc.	Industrials	4.11%
TYL	Tyler Technologies, Inc.	Technology	3.84%
CPRT	Copart, Inc.	Consumer Discretionary	3.56%
GWRE	Guidewire Software, Inc.	Technology	3.40%
VEEV	Veeva Systems, Inc.	Health Care	3.31%
CSGP	CoStar Group, Inc.	Real Estate	3.24%
Total within the Composite:			44.16%

The positions represent Conestoga Capital Advisors largest equity holdings based on the aggregate dollar value of positions held in the client accounts that are included in the Mid Cap Composite. All information is provided for informational purposes only and should not be deemed as a recommendation to buy the securities mentioned. Sectors are defined according to the ICB industry definitions.



**Important Information: GIPS®-Compliant Performance Information for the Period Ending December 31, 2025**

Year Return	Conestoga Small Cap Equity Composite Total Net Return	Russell 2000 Growth Total Return	# of Portfolios	Composite Dispersion (%)	Composite Assets at End of Period \$ (Millions)	% of Firm Assets	Firm Assets \$ (Millions)	UMA Assets \$ (Millions)	Total Assets \$ (Millions)
2025	-10.13%	13.01%	146	0.49	\$1,287.4	20%	\$6,371.4	\$563.6	\$6,935.0
2024	9.59%	15.15%	163	0.42	\$1,720.4	21%	\$8,079.1	\$677.1	\$8,756.2
2023	21.94%	18.66%	163	0.52	\$1,634.3	23%	\$7,190.5	\$630.8	\$7,821.3
2022	-27.84%	-26.36%	154	0.44	\$1,290.5	23%	\$5,708.7	\$517.1	\$6,225.8
2021	16.94%	2.83%	155	0.79	\$1,815.7	22%	\$8,165.1	\$718.5	\$8,883.6
2020	31.09%	34.63%	156	0.96	\$1,641.7	24%	\$6,834.1	\$504.5	\$7,338.6
2019	26.31%	28.48%	144	0.57	\$1,500.7	32%	\$4,707.3	\$156.1	\$4,863.4
2018	1.30%	-9.31%	134	0.47	\$1,266.3	35%	\$3,633.1	\$66.3	\$3,699.4
2017	29.00%	22.17%	117	0.55	\$958.4	35%	\$2,730.2	\$35.6	\$2,765.8
2016	15.57%	11.32%	111	0.50	\$833.5	46%	\$1,798.1	\$15.1	\$1,813.2
2015	7.83%	-1.38%	99	0.51	\$867.8	55%	\$1,591.8	\$7.0	\$1,598.8

**Annualized Rate of Return for the Period Ending December 31, 2025**

Time Period	Conestoga Small Cap Equity Composite Total Net Return	Russell 2000 Growth Total Return
1 Year	-10.13%	13.01%
3 Years	6.30%	15.59%
5 Years	0.27%	3.18%
10 Years	9.74%	9.57%
Since Inception (12/31/98)	10.43%	7.28%

Conestoga Capital Advisors, LLC claims compliance with the Global Investment Performance Standards (GIPS) and has prepared and presented this report in compliance with the GIPS standards. Conestoga Capital Advisors, LLC has been independently verified for the periods December 31, 1998 through March 31, 2025 by independent verifiers.

A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm's policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. The Conestoga Small Cap Equity Composite ("Composite") has had a performance examination for the periods December 31, 1998 through March 31, 2025. The verification and performance examination reports are available upon request.

A complete list and description of all composites and policies for valuing portfolios, calculating and reporting returns, and preparing GIPS reports are available upon request. Performance results are presented after all actual investment management fees, custodial fees, commissions, and other trading expenses. Computations assume the reinvestment of all dividends and capital gains. Portfolios are valued monthly, and returns are weighted by using beginning-of-quarter values plus weighted cash flows. Annual returns are calculated by geometrically linking the monthly returns. Performance results for the full historical period are total net return, time-weighted rates of return expressed in U.S. dollars. Trade date accounting is used for all periods. No leverage has been used in the accounts included in the

### **Important Information: GIPS®-Compliant Performance Information for the Period Ending December 31, 2025**

Composite. The actual return and value of an account will fluctuate and at any point could be worth more or less than the amount invested. Individual account performance will vary according to individual investment objectives.

All fee-paying discretionary portfolios will be assigned to an appropriate composite according to investment objective. Composites will include new portfolios at the start of the next performance measurement period (i.e. the beginning of the next month) after the portfolio comes under management and will exclude terminated portfolios after the last full calendar month period the portfolios were under management (i.e., the end of the last full calendar month), but composites will continue to include terminated portfolios for all periods prior to termination.

The Russell 2000 Index is comprised of the smallest 2000 companies in the Russell 3000 Index, representing approximately 10% of the Russell 3000 total market capitalization. Conestoga removed the Russell 2000 Index as a secondary benchmark for the Composite on 9/30/2022. The benchmark for the Composite is the Russell 2000 Growth Index, which measures the performance of the small-cap growth segment of the U.S. equity universe. It includes those Russell 2000 companies with higher price-to-value ratios and higher forecasted growth values. The volatility of the Russell 2000 Growth Index may be materially different from that of the Composite. In addition, the Composite's holdings may differ significantly from the securities that comprise the Russell 2000 Growth Index. For comparison purposes, the Composite is measured against the Russell 2000 Growth Indices. (Source: Russell)

UMA assets presented are not part of Conestoga's GIPS-defined firm assets as Conestoga has no trading authority over these assets and serves in an advisory-only capacity. UMA assets under management are received on a preliminary quarterly basis, which are subject to change by the plan sponsor after a complete reconciliation of the underlying accounts. The "Total Assets" include UMA assets and are not part of the GIPS firm assets. UMA and Total Assets are shown as supplemental information.

The current management fee schedule is as follows: Up to \$25,000,000 = 1.00%; Over \$25,000,000 = Negotiable.

The dispersion of annual returns is measured by the standard deviation across equal-weighted portfolio returns represented within the Composite for the full year. Dispersion is shown as "N/A" for periods less than one year and for periods with 5 or fewer composite members for the entire year.

As of December 31, 2025, the three-year standard deviation, calculated net of fees, for the Conestoga Small Cap Equity Composite was 17.66% and the Russell 2000 Growth was 20.04%. As of December 31, 2024, the three-year standard deviation, calculated net of fees, for the Conestoga Small Cap Equity Composite was 21.77% and the Russell 2000 Growth was 23.99%. As of December 31, 2023, the three-year standard deviation, calculated net of fees, for the Conestoga Small Cap Equity Composite was 19.87% and the Russell 2000 Growth was 21.79%.

Conestoga Capital Advisors, LLC is an independent registered investment advisory firm specializing in small and mid cap portfolio management. Performance results prior to June 30, 2001 have been achieved by Martindale Andres & Company, Inc., William Martindale and Robert Mitchell's prior investment advisory firm. The Conestoga Small Cap Equity Composite creation date and inception date is December 31, 1998. The Composite contains fee paying, discretionary portfolios which primarily invest in small cap equities. In addition, for an account to be included in the Composite, no more than 20% of the portfolio will (i) have a market capitalization outside the range of the Russell 2000 Index; or (ii) be outside of the small capitalization model. In addition, the weighting of an individual security within a given account cannot exceed 10% (or 2.5 times the target weighting defined in the small capitalization model portfolio) of the equity assets. Portfolios that are less than \$250,000 in size at inception are not included in this Composite. Prior to September 30, 2003, portfolios greater than \$100,000 were included in this Composite. As of December 31, 2021, the Composite definition was redefined. Previously, the market capitalization size range was calculated using a rolling 3-year average of the Russell 2000 Growth Index. Portfolios will not be removed from the assigned composite if they fall below the minimum simply due to market depreciation. There have not been any material changes in the personnel responsible for managing accounts during the time period. **Past performance is not indicative of future results.**

GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.

**Important Information: GIPS®-Compliant Performance Information for the Period Ending December 31, 2025**

Year Return	Conestoga SMid Cap Equity Composite Total Net Return	Russell 2500 Growth Total Return	# of Portfolios	Composite Dispersion (%)	Composite Assets at End of Period \$ (Millions)	% of Firm Assets	Firm Assets \$ (Millions)	UMA Assets \$ (Millions)	Total Assets \$ (Millions)
2025	-4.71%	10.31%	22	0.42	\$686.0	11%	\$6,371.4	\$563.6	\$6,935.0
2024	11.36%	13.90%	22	0.22	\$667.1	8%	\$8,079.1	\$677.1	\$8,756.2
2023	26.61%	18.93%	24	0.44	\$580.0	8%	\$7,190.5	\$630.8	\$7,821.3
2022	-29.45%	-26.21%	29	0.38	\$494.9	9%	\$5,708.7	\$517.1	\$6,225.8
2021	16.57%	5.04%	27	0.30	\$683.6	8%	\$8,165.1	\$718.5	\$8,883.6
2020	30.89%	40.47%	11	0.54	\$538.5	8%	\$6,834.2	\$504.4	\$7,338.6
2019	35.96%	32.65%	7	1.05	\$88.3	2%	\$4,707.3	\$156.1	\$4,863.4
2018	0.69%	-7.47%	4	0.21	\$68.6	2%	\$3,633.1	\$66.3	\$3,699.4
1/31/17 - 12/31/17	32.69%	21.58%	2	N/A	\$59.6	2%	\$2,730.2	\$35.6	\$2,765.8
12/31/13-5/31/14	-12.28%	-1.23%	1	N/A	\$66.8	4%	\$1,652.7	N/A	\$1,652.7

**Annualized Rate of Return for the Period Ending December 31, 2025**

Time Period	Conestoga SMid Cap Equity Composite Total Net Return	Russell 2500 Growth Total Return
1 Year	-4.71%	10.31%
3 Years	10.34%	14.32%
5 Years	2.01%	2.98%
Since Inception (1/31/17)	11.44%	10.46%

Conestoga Capital Advisors, LLC claims compliance with the Global Investment Performance Standards (GIPS) and has prepared and presented this report in compliance with the GIPS standards. Conestoga Capital Advisors, LLC has been independently verified for the periods December 31, 1998 through March 31, 2025 by independent verifiers.

A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm's policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. The Conestoga SMid Cap Equity Composite ("Composite") has had a performance examination for the periods December 31, 2013 through March 31, 2025. The verification and performance examination reports are available upon request.

A complete list and description of all composites and policies for valuing portfolios, calculating and reporting returns, and preparing GIPS reports are available upon request. Performance results are presented after all actual investment management fees, custodial fees, commissions, and other trading expenses. Computations assume the reinvestment of all dividends and capital gains. Portfolios are valued monthly, and returns are weighted by using beginning-of-quarter values plus weighted cash flows. Annual returns are calculated by geometrically linking the monthly returns. Performance results for the full historical period are total net return, time-weighted rates of return expressed in U.S. dollars. Trade date accounting is used for all periods. No leverage has been used in the accounts included in the Composite. The actual return and value of an account will fluctuate and at any point could be worth more or less than the amount invested. Individual account performance will vary according to individual investment objectives.

### **Important Information: GIPS®-Compliant Performance Information for the Period Ending December 31, 2025**

All fee-paying discretionary portfolios will be assigned to an appropriate composite according to investment objective. Composites will include new portfolios at the start of the next performance measurement period (i.e. the beginning of the next month) after the portfolio comes under management and will exclude terminated portfolios after the last full calendar month period the portfolios were under management (i.e., the end of the last full calendar month), but composites will continue to include terminated portfolios for all periods prior to termination.

The Russell 2500 Index measures the performance of the small to mid-cap segment of the U.S. equity universe, commonly referred to as "SMid" cap. The Russell 2500 Index is a subset of the Russell 3000® Index. It includes approximately 2500 of the smallest securities based on a combination of their market cap and current index membership. The Russell 2500 Index is constructed to provide a comprehensive and unbiased barometer for the small to mid-cap segment. The benchmark for this Composite is the Russell 2500 Growth Index, which measures the performance of the small to mid-cap growth segment of the U.S. equity universe. It includes those Russell 2500 companies with higher price-to-book ratios, forecasted growth values, and historical sales per share. Index returns are provided for comparison purposes to represent the investment environment existing during the time periods shown. An index is fully invested, includes the reinvestment of dividends and capital gains, but does not include any transaction costs, management fees, or other costs. Holdings of each separately managed account in a composite will differ from the index. An investor may not invest directly in an index. (Source: Russell)

UMA assets presented are not part of Conestoga's GIPS-defined firm assets as Conestoga has no trading authority over these assets and serves in an advisory-only capacity. UMA assets under management are received on a preliminary quarterly basis, which are subject to change by the plan sponsor after a complete reconciliation of the underlying accounts. The "Total Assets" include UMA assets and are not part of the GIPS firm assets. UMA and Total Assets are shown as supplemental information.

The current management fee schedule is as follows: Up to \$25,000,000 = 1.00%; Over \$25,000,000 = Negotiable.

The dispersion of annual returns is measured by the standard deviation across equal-weighted portfolio returns represented within the Composite for the full year. Dispersion is shown as "N/A" for periods less than one year and for periods with 5 or fewer composite members for the entire year.

As of December 31, 2025, the three-year standard deviation, calculated net of fees, for the Conestoga SMid Cap Equity Composite was 16.68% and the Russell 2500 Growth was 18.84%. As of December 31, 2024, the three-year standard deviation, calculated net of fees, for the Conestoga SMid Cap Equity Composite was 22.28% and the Russell 2500 Growth was 22.80%. As of December 31, 2023, the three-year standard deviation, calculated net of fees, for the Conestoga SMid Cap Equity Composite was 21.11% and the Russell 2500 Growth was 20.97%.

Conestoga Capital Advisors, LLC is an independent registered investment advisory firm specializing in small and mid cap portfolio management. The Conestoga SMid Cap Equity Composite creation date and inception date is December 31, 2013. In June 2014, the Composite lost its member portfolio, and, as a result, the Composite had no member portfolios. Reporting of the Composite resumed in January 2017, when a portfolio was added to the Composite. The Composite includes all dedicated SMid Cap equity portfolios. This Composite contains fee-paying, discretionary portfolios which primarily invest in Mid Cap and Small Cap equities. In addition, for an account to be included in the Composite, no more than 20% of the assets can have a market capitalization outside the size range of the Russell 2500 Index. Portfolios that are less than \$250,000 in size at inception are not included in this Composite. Portfolios will not be removed from the assigned composite if they fall below the minimum simply due to market depreciation. As of December 31, 2021, the Composite definition was redefined. Previously, the market capitalization size range was calculated using a rolling 3-year average of the Russell 2500 Growth Index. **Past performance is not indicative of future results.**

GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.

**Important Information: GIPS®-Compliant Performance Information for the Period Ending December 31, 2025**

Year Return	Conestoga Micro Cap Equity Composite Total Net Return	Russell Microcap Growth Total Return	# of Portfolios	Composite Dispersion (%)	Composite Assets at End of Period \$ (Millions)	% of Firm Assets	Firm Assets \$ (Millions)	UMA Assets \$ (Millions)	Total Assets \$ (Millions)
2025	16.24%	21.84%	4	N/A	\$49.7	0.8%	\$6,371.4	\$563.6	\$6,935.0
2024	13.52%	21.91%	4	N/A	\$42.6	0.5%	\$8,079.1	\$677.1	\$8,756.2
2023	-1.02%	9.11%	4	N/A	\$37.3	0.5%	\$7,190.5	\$630.8	\$7,821.3
2022	-27.68%	-29.76%	4	N/A	\$37.6	0.7%	\$5,708.7	\$517.1	\$6,225.8
2021	5.63%	0.88%	4	N/A	\$52.0	0.6%	\$8,165.1	\$718.5	\$8,883.6
2020	75.60%	40.13%	1	N/A	\$34.6	0.5%	\$6,834.1	\$504.5	\$7,338.6

**Annualized Rate of Return for the Period Ending December 31, 2025**

Time Period	Conestoga Micro Cap Equity Composite Total Net Return	Russell Microcap Growth Total Return
1 Year	16.24%	21.84%
3 Years	9.31%	17.46%
5 Years	-0.04%	2.81%
Since Inception (12/31/19)	9.80%	8.25%

Conestoga Capital Advisors, LLC claims compliance with the Global Investment Performance Standards (GIPS) and has prepared and presented this report in compliance with the GIPS standards. Conestoga Capital Advisors, LLC has been independently verified for the periods December 31, 1998 through March 31, 2025 by independent verifiers.

A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm's policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. The Conestoga Micro Cap Equity Composite ("Composite") has had a performance examination for the periods December 31, 2019 through March 31, 2025. The verification and performance examination reports are available upon request.

A complete list and description of all composites and policies for valuing portfolios, calculating and reporting returns, and preparing GIPS reports are available upon request. Performance results are presented after all actual investment management fees, custodial fees, commissions, and other trading expenses. Computations assume the reinvestment of all dividends and capital gains. Portfolios are valued monthly, and returns are weighted by using beginning-of-quarter values plus weighted cash flows. Annual returns are calculated by geometrically linking the monthly returns. Performance results for the full historical period are total net return, time-weighted rates of return expressed in U.S. dollars. Trade date accounting is used for all periods. No leverage has been used in the accounts included in the Composite. The actual return and value of an account will fluctuate and at any point could be worth more or less than the amount invested. Individual account performance will vary according to individual investment objectives.

All fee-paying discretionary portfolios will be assigned to an appropriate composite according to investment objective. Composites will include new portfolios at the start of the next performance measurement period (i.e. the beginning of the next month) after the portfolio comes under management and will exclude terminated portfolios after the last full calendar month period the portfolios were under management (i.e., the end of the last full calendar month), but composites will continue to include terminated portfolios for all periods prior to termination.

Index returns are provided for comparison purposes to represent the investment environment existing during the time periods shown. An index is fully invested, includes the reinvestment of dividends and capital gains, but does not include



**Important Information: GIPS®-Compliant Performance Information for the Period Ending December 31, 2025**

any transaction costs, management fees, or other costs. Holdings of each separately managed account in a composite will differ from the index. An investor may not invest directly in an index. The benchmark for this Composite is the Russell Microcap Growth Index, which measures the performance of the microcap growth segment of the U.S. equity market. It includes Russell Microcap companies that are considered more growth oriented relative to the overall market as defined by Russell's leading style methodology. The Russell Microcap Growth Index is constructed to provide a comprehensive and unbiased barometer for the microcap growth segment of the market. The Index is completely reconstituted annually to ensure larger stocks do not distort performance and characteristics of the microcap opportunity set. (Source: Russell)

UMA assets presented are not part of Conestoga's GIPS-defined firm assets as Conestoga has no trading authority over these assets and serves in an advisory-only capacity. UMA assets under management are received on a preliminary quarterly basis, which are subject to change by the plan sponsor after a complete reconciliation of the underlying accounts. The "Total Assets" include UMA assets and are not part of the GIPS firm assets. UMA and Total Assets are shown as supplemental information.

The current management fee schedule is as follows: Up to \$25,000,000 = 1.00%; Over \$25,000,000 = Negotiable.

The dispersion of annual returns is measured by the standard deviation across equal-weighted portfolio returns represented within the Composite for the full year. Dispersion is shown as "N/A" for periods less than one year and for periods with 5 or fewer composite members for the entire year.

As of December 31, 2025, the three-year standard deviation, calculated net of fees, for the Conestoga Micro Cap Equity Composite was 23.19% and the Russell Microcap Growth was 22.80%. As of December 31, 2024, the three-year standard deviation, calculated net of fees, for the Conestoga Micro Cap Equity Composite was 26.31% and the Russell Microcap Growth was 25.31%. As of December 31, 2023, the three-year standard deviation, calculated net of fees, for the Conestoga Micro Cap Equity Composite was 24.82% and the Russell Microcap Growth was 24.69%.

Conestoga Capital Advisors, LLC is an independent registered investment advisory firm specializing in small and mid cap portfolio management. The Conestoga Micro Cap Equity Composite creation date and inception date is December 31, 2019. This Composite contains fee-paying, discretionary portfolios which primarily invest in micro cap equities. For an account to be included in the Composite, the market capitalization will be within the size range of the Russell Microcap Index at the time of initial purchase. All portfolios have more than \$250,000 in assets. As of June 18, 2021, the Composite definition was redefined. Previously, the market capitalization size range was calculated using a rolling 3-year average of the Russell Microcap Growth Index. Portfolios will not be removed from the assigned composite if they fall below the minimum simply due to market depreciation. **Past performance is not indicative of future results.**

GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.

**Important Information: GIPS®-Compliant Performance Information for the Period Ending December 31, 2025**

Year Return	Conestoga Mid Cap Equity Composite Total Net Return	Russell Midcap Growth Total Return	# of Portfolios	Composite Dispersion (%)	Composite Assets at End of Period \$ (Millions)	% of Firm Assets	Firm Assets \$ (Millions)	UMA Assets \$ (Millions)	Total Assets \$ (Millions)
2025	-4.73%	8.66%	9	0.55	\$13.4	0.2%	\$6,371.4	\$563.6	\$6,935.0
2024	4.36%	22.10%	10	0.18	\$17.9	0.2%	\$8,079.1	\$677.1	\$8,756.2
2023	22.83%	25.87%	12	0.35	\$18.9	0.3%	\$7,190.5	\$630.8	\$7,821.3
2022	-29.66%	-26.72%	10	0.33	\$16.2	0.3%	\$5,708.7	\$517.1	\$6,225.8
2021	17.60%	12.73%	10	0.22	\$23.4	0.3%	\$8,165.1	\$718.5	\$8,883.6
2020	31.29%	35.59%	9	0.79	\$18.3	0.3%	\$6,834.1	\$504.5	\$7,338.6
2019	33.68%	35.47%	9	1.01	\$15.9	0.3%	\$4,707.3	\$156.1	\$4,863.4
2018	-1.55%	-4.75%	9	0.84	\$12.1	0.3%	\$3,633.1	\$66.3	\$3,699.4
2017	33.00%	25.27%	9	0.58	\$12.3	0.5%	\$2,730.2	\$35.6	\$2,765.8
2016	10.26%	7.33%	9	1.54	\$9.4	0.5%	\$1,798.1	\$15.1	\$1,813.2
2015	2.21%	-0.20%	8	0.43	\$8.3	0.5%	\$1,591.8	\$7.0	\$1,598.8

**Annualized Rate of Return for the Period Ending December 31, 2025**

Time Period	Conestoga Mid Cap Equity Composite Total Net Return	Russell Midcap Growth Total Return
1 Year	-4.73%	8.66%
3 Years	6.89%	18.64%
5 Years	0.20%	6.65%
10 Years	9.86%	12.49%
Since Inception (3/31/10)	10.21%	12.70%

Conestoga Capital Advisors, LLC claims compliance with the Global Investment Performance Standards (GIPS) and has prepared and presented this report in compliance with the GIPS standards. Conestoga Capital Advisors, LLC has been independently verified for the periods December 31, 1998 through March 31, 2025 by independent verifiers.

A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm's policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. The Conestoga Mid Cap Equity Composite ("Composite") has had a performance examination for the periods March 10, 2010 through March 31, 2025. The verification and performance examination reports are available upon request.

A complete list and description of all composites and policies for valuing portfolios, calculating and reporting returns, and preparing GIPS reports are available upon request. Performance results are presented after all actual investment management fees, custodial fees, commissions, and other trading expenses. Computations assume the reinvestment of all dividends and capital gains. Portfolios are valued monthly, and returns are weighted by using beginning-of-quarter values plus weighted cash flows. Annual returns are calculated by geometrically linking the monthly returns. Performance results for the full historical period are total net return, time-weighted rates of return expressed in U.S. dollars. Trade date accounting is used for all periods. No leverage has been used in the accounts included in the



**Important Information: GIPS®-Compliant Performance Information for the Period Ending December 31, 2025**

Composite. The actual return and value of an account will fluctuate and at any point could be worth more or less than the amount invested. Individual account performance will vary according to individual investment objectives.

All fee-paying discretionary portfolios will be assigned to an appropriate composite according to investment objective. Composites will include new portfolios at the start of the next performance measurement period (i.e. the beginning of the next month) after the portfolio comes under management and will exclude terminated portfolios after the last full calendar month period the portfolios were under management (i.e., the end of the last full calendar month), but composites will continue to include terminated portfolios for all periods prior to termination.

The benchmark for this composite is the Russell Mid Cap Growth Index, which measures the performance of those Russell Midcap companies with higher price/book ratios and higher forecasted growth values. The stocks are also members of the Russell 1000® Growth Index. Index returns are provided for comparison purposes to represent the investment environment existing during the time periods shown. An index is fully invested, includes the reinvestment of dividends and capital gains, but does not include any transaction costs, management fees, or other costs. Holdings of each separately managed account in a composite will differ from the index. An investor may not invest directly in an index. (Source: Russell)

UMA assets presented are not part of Conestoga's GIPS-defined firm assets as Conestoga has no trading authority over these assets and serves in an advisory-only capacity. UMA assets under management are received on a preliminary quarterly basis, which are subject to change by the plan sponsor after a complete reconciliation of the underlying accounts. The "Total Assets" include UMA assets and are not part of the GIPS firm assets. UMA and Total Assets are shown as supplemental information.

The current management fee schedule is as follows: Up to \$25,000,000 = 1.00%; Over \$25,000,000 = Negotiable.

The dispersion of annual returns is measured by the standard deviation across equal-weighted portfolio returns represented within the Composite for the full year. Dispersion is shown as "N/A" for periods less than one year and for periods with 5 or fewer composite members for the entire year.

As of December 31, 2025, the three-year standard deviation, calculated net of fees, for the Conestoga Mid Cap Equity Composite was 14.64% and the Russell Midcap Growth was 17.59%. As of December 31, 2024, the three-year standard deviation, calculated net of fees, for the Conestoga Mid Cap Equity Composite was 20.82% and the Russell Midcap Growth was 22.15%. As of December 31, 2023, the three-year standard deviation, calculated net of fees, for the Conestoga Mid Cap Equity Composite was 21.29% and the Russell Midcap Growth was 21.06%.

Conestoga Capital Advisors, LLC is an independent registered investment advisory firm specializing in small and mid cap portfolio management. The Conestoga Mid Cap Equity Composite creation date and inception date is March 31, 2010. This Composite contains fee-paying, discretionary portfolios which primarily invest in Mid Cap equities. For an account to be included in the Composite, no more than 20% of the assets can have a market capitalization outside the size range of the Russell Mid Cap Index at the time of initial purchase. All portfolios have more than \$250,000 in assets. As of June 18, 2021, the Composite definition was redefined. Previously, the market capitalization size range was calculated using a rolling 3-year average of the Russell Mid Cap Growth Index. Portfolios will not be removed from the assigned composite if they fall below the minimum simply due to market depreciation. **Past performance is not indicative of future results.**

GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.